Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05916950 · ClinicalTrials.gov registry record · NA
The THOR IDE Study
A NA study of Peripheral Artery Disease and PAD, sponsored by Philips Clinical & Medical Affairs Global.
- Recruiting
- Registry status
- NA
- Development phase
- 155
- Enrollment target
- 20
- Study locations
NCT05916950 is a NA study of Peripheral Artery Disease and PAD that is actively recruiting participants, run by Philips Clinical & Medical Affairs Global. The registered enrollment target is 155 participants, above the 124-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (25% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT05916950, a NA study of Peripheral Artery Disease and PAD, is actively recruiting participants, sponsored by Philips Clinical & Medical Affairs Global.
- RECRUITING
- Registry status
- NA
- Development phase
- 155 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to test the Thor system in adult (≥ 18 year old) patients with de novo (new, never treated) calcified lesions in infrainguinal (leg) arteries (peripheral artery disease or PAD). The main question\[s\] it aims to answer are: * Is the Thor system safe in treating these lesions * Does the Thor system work to treat these lesions Participants will: * Receive treatment with the Thor system * Have follow-up visits at Discharge, 30 days, 6 months, and 12 months
Conditions Studied
Interventions
- DEVICE Thor laser atherectomy
Study Locations (20)
Florida
- Manatee Memorial Hospital - Bradenton
- Tallahassee Research Institute - Tallahassee
- Guardian Research Organization - Winter Park
New Jersey
- Deborah Heart and Lung Center - Browns Mills
- Heart and Vascular Institute of Central Jersey - New Brunswick
- Atlantic Medical Imaging of New jersey - Vineland
Louisiana
- Cardiovascular Institute of the South - Houma
- Cardiovascular Institute of the South - Lafayette
Massachusetts
- Southcoast Hospitals/Charlton Memorial Hospital - Fall River
- Vascular Breakthroughs - Leominster
Michigan
- Henry Ford St John Hospital - Detroit
- Henry Ford Hospital - Detroit
New York
- Mount Sinai Hospital - New York
- New York Presbyterian Hospital/Columbia University Irving Medical Center - New York
California
- St. Helena Hospital - St. Helena
Colorado
- Rocky Mountain Regional VA Medical Center - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2024-10-29 |
| Est. Completion | 2027-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05916950
The ClinicalTrials.gov registry entry for NCT05916950 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 124-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (25% higher). The listed sponsor is Philips Clinical & Medical Affairs Global, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Peripheral Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Thor laser atherectomy is the first listed.
NCT05916950 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, New Jersey, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05916950 about?
NCT05916950 is a clinical study titled "The THOR IDE Study". The goal of this clinical trial is to test the Thor system in adult (≥ 18 year old) patients with de novo (new, never treated) calcified lesions in infrainguinal (leg) arteries (peripheral artery disease or PAD). The main question\[s\] it aims to answer are: * Is the Thor system safe in treating t...
What is the current status of trial NCT05916950?
This trial is currently recruiting. It is a NA study. The enrollment target is 155 participants. The study started on 2024-10-29. Estimated completion is 2027-12.
What conditions does trial NCT05916950 study?
This clinical trial studies the following conditions: Peripheral Artery Disease, PAD, Peripheral Artery Stenosis, Peripheral Artery Calcification.
What interventions are being tested in trial NCT05916950?
The interventions under investigation include: Thor laser atherectomy (DEVICE).
Who is sponsoring clinical trial NCT05916950?
This trial is sponsored by Philips Clinical & Medical Affairs Global, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05916950 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Iowa, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease
RECRUITING · NA
-
BEETroot Juice to Reverse Functional Impairment in PAD
RECRUITING · NA
-
Telehealth Delivered Home-based Walking for Vets With Peripheral Artery Disease
RECRUITING · NA
-
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy
RECRUITING · NA
-
Leg Heat Therapy in Peripheral Artery Disease
RECRUITING · NA
-
Oxygen-guided Supervised Exercise Therapy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.